Market assessment for novel, natural product derived animal health therapeutics

新型天然产物动物健康疗法的市场评估

• 批准号: 700550
• 金额: $ 3.19万
• 依托单位: ACIDOPHIL LTD.
• 依托单位国家: 英国
• 项目类别: GRD Proof of Market
• 财政年份: 2015
• 资助国家: 英国
• 起止时间: 2015 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=700550
• 关键词: Market; assessment; novel; natural; product

Acidophil is laying the groundwork for a UK-based animal health biotech company and hason-going programs to develop novel natural product based medicines. This project aims tofurther develop Acidophil’s view of optimal routes to market with an emphasis on regulatoryand competitive environments and patent landscape. This information is necessary to supportefforts to raise investment necessary to develop this opportunity and build value for the UKeconomy.Animal health is a compelling market, but relatively neglected by biotechnology. The globalanimal health industry for livestock and companion animals is £60-67 billion, with medicinescomprising £22 billion of the market. Agriculture, both crops and livestock, is a key pillar ofthe UK economy. The UK is famously a nation of animal enthusiasts, with a large populationof companion animals.. European sales accounted for 32% of the worldwide animal medicinesales, making it the second largest market after the United States.Threats to animal health are costly: for example livestock losses due to invertebrate pests total£34 billion worldwide each year. Additionally, the long-term task of preventing animaldiseases costs the UK about £100 million per year. Agents currently used to protect livestockare gradually losing effectiveness due to development of resistance and emergence of newpests, yet few new agents are entering the market.Acidophil’s innovation consists of using synthetic biology and chemistry to make novel andimproved parasiticides that can overcome pest resistance and target a broad range of pests.Success will result in valuable products for livestock and companion animal protection. Thisprogram of research and resultant intellectual property are being supported, in part, byInnovate UK through the Agri-Tech Catalyst scheme. While the development of activecompounds is underway, the question of where they deliver the most value in animal healthremains.

嗜酸菌正在为一家总部位于英国的动物健康生物技术公司奠定基础，并正在进行开发新型天然产品药物的计划。该项目旨在进一步发展嗜酸菌对市场最佳途径的看法，重点是监管和竞争环境以及专利景观。这些信息是必要的，以筹集必要的投资，以开发这一机会，并建立价值的英国经济。动物健康是一个引人注目的市场，但相对忽视的生物技术。全球牲畜和伴侣动物的动物健康产业价值600 - 670亿英镑，其中药物占220亿英镑的市场。农业，包括农作物和牲畜，是英国经济的重要支柱。英国是一个著名的动物爱好者的国家，拥有大量的伴侣动物。欧洲销售额占全球兽药销售额的32%，使其成为仅次于美国的第二大市场。动物健康受到的威胁代价高昂：例如，全球每年因无脊椎动物害虫造成的牲畜损失总计340亿英镑。此外，预防动物疾病的长期任务每年花费英国约1亿英镑。目前用于保护牲畜的药剂由于抗药性的发展和新害虫的出现而逐渐失去效力，但很少有新的药剂进入市场。嗜酸菌的创新包括使用合成生物学和化学来制造新型和改进的杀寄生虫剂，可以克服害虫抗药性并针对广泛的害虫。成功将为牲畜和伴侣动物保护带来有价值的产品。这一研究计划和由此产生的知识产权得到了英国创新署通过农业技术催化剂计划的部分支持。虽然活性化合物的开发正在进行中，但它们在动物健康中发挥最大价值的问题仍然存在。